Sarah Aebersold Sells 4,000 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 4,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $17.65, for a total transaction of $70,600.00. Following the sale, the insider now directly owns 65,843 shares of the company’s stock, valued at approximately $1,162,128.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Sarah Aebersold also recently made the following trade(s):

• On Wednesday, February 21st, Sarah Aebersold sold 58 shares of BioLife Solutions stock. The shares were sold at an average price of $17.35, for a total transaction of $1,006.30.
• On Tuesday, January 23rd, Sarah Aebersold sold 336 shares of BioLife Solutions stock. The shares were sold at an average price of $17.11, for a total transaction of $5,748.96.

BioLife Solutions Stock Up 1.1 %

BioLife Solutions stock opened at $17.51 on Friday. The company has a market cap of $793.20 million, a P/E ratio of -11.52 and a beta of 1.67. BioLife Solutions, Inc. has a 1-year low of $8.92 and a 1-year high of $24.50. The company has a fifty day simple moving average of $17.74 and a 200 day simple moving average of $15.09. The company has a current ratio of 2.86, a quick ratio of 1.83 and a debt-to-equity ratio of 0.06.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. Research analysts anticipate that BioLife Solutions, Inc. will post -0.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Jefferies Financial Group started coverage on shares of BioLife Solutions in a research report on Thursday. They issued a “buy” rating and a $22.00 target price for the company. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $23.40.

Institutional Trading of BioLife Solutions

A number of large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its stake in BioLife Solutions by 5.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 11,437 shares of the medical equipment provider’s stock valued at $249,000 after acquiring an additional 571 shares during the last quarter. Nuveen Asset Management LLC lifted its stake in BioLife Solutions by 0.8% in the fourth quarter. Nuveen Asset Management LLC now owns 80,160 shares of the medical equipment provider’s stock valued at $1,303,000 after acquiring an additional 602 shares during the last quarter. Macquarie Group Ltd. lifted its stake in BioLife Solutions by 1.1% in the second quarter. Macquarie Group Ltd. now owns 73,437 shares of the medical equipment provider’s stock valued at $1,014,000 after acquiring an additional 766 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in BioLife Solutions by 2.3% in the second quarter. Envestnet Asset Management Inc. now owns 35,066 shares of the medical equipment provider’s stock valued at $775,000 after acquiring an additional 793 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of BioLife Solutions by 6.9% during the 1st quarter. Jane Street Group LLC now owns 13,377 shares of the medical equipment provider’s stock worth $304,000 after buying an additional 858 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.